Sugi Predict

Sugi Predict / Compounds / SCHEMBL2002397

SCHEMBL2002397

SCHEMBL2002397

Nc1cccc2cncc(Cl)c12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 3/20 0.46
▸ LMNA P02545 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ GAA P10253 2/20 0.42
▸ TSHR P16473 3/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ NR4A2 P43354 2/20 0.38
▸ HPGD P15428 1/20 0.35
▸ KEAP1 Q14145 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ IMPDH2 P12268 1/20 0.35
▸ JAK2 O60674 1/20 0.35
▸ RPS6KA3 P51812 1/20 0.35
▸ MELK Q14680 1/20 0.35
▸ STK24 Q9Y6E0 1/20 0.35
▸ PIK3CA P42336 1/20 0.34
▸ CDK2 P24941 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27192076 0.84 CYP1A2 (0.41) CYP3A4LMNACYP1A2CYP2D6CYP2C9
SCHEMBL31732851 0.81 CYP3A4 (0.50) CYP3A4LMNACYP1A2CYP2D6CYP2C9
SCHEMBL637008 0.81 CYP3A4 (0.50) CYP3A4LMNACYP1A2CYP2D6CYP2C9
SCHEMBL30064915 0.76 TSHR (0.52) CYP3A4CYP1A2GAATSHRALDH1A1
SCHEMBL4076360 0.76 TSHR (0.52) CYP3A4CYP1A2GAATSHRALDH1A1
SCHEMBL5657552 0.76 CYP3A4 (0.46) CYP3A4LMNACYP1A2CYP2D6CYP2C9
SCHEMBL998210 0.76 CYP3A4 (0.46) CYP3A4LMNACYP1A2CYP2D6CYP2C9
SCHEMBL18599582 0.76 AHR (0.35) CYP1A2GAAALDH1A1NOS1KDM4E
SCHEMBL18495138 0.76 BDKRB2 (0.38) CYP3A4CYP1A2GAATSHRALDH1A1
SCHEMBL30065660 0.76 CYP3A4 (0.46) CYP3A4LMNACYP1A2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113227054-B ROCK kinase inhibitors 切尔韦洛治疗有限责任公司 2025-04-11 — — CN disclosed
EP-3877364-B1 ROCK KINASE INHIBITORS Cervello Therapeutics LLC (US) 2024-08-21 — — EP disclosed
US-11912719-B2 Substituted isoquinolines as rock kinase inhibitors CERVELLO THERAPEUTICS, LLC. (US) 2024-02-27 — — US disclosed
US-11912719-B2 Substituted isoquinolines as rock kinase inhibitors CERVELLO THERAPEUTICS, LLC. (US) 2024-02-27 — — US disclosed
US-11912719-B2 Substituted isoquinolines as rock kinase inhibitors CERVELLO THERAPEUTICS, LLC. (US) 2024-02-27 — — US disclosed
US-20220119406-A1 SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS Cervello Therapeutics LLC (US) 2022-04-21 — — US disclosed
US-20220119406-A1 SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS Cervello Therapeutics LLC (US) 2022-04-21 — — US disclosed
US-11248004-B2 Substituted isoquinolines as rock kinase inhibitors CERVELLO THERAPEUTICS, LLC. (US) 2022-02-15 — — US disclosed
US-11248004-B2 Substituted isoquinolines as rock kinase inhibitors CERVELLO THERAPEUTICS, LLC. (US) 2022-02-15 — — US disclosed
CN-113227054-A ROCK kinase inhibitors 切尔韦洛治疗有限责任公司 2021-08-06 — — CN disclosed
EP-2130828-A1 SULFONAMIDE DERIVATIVE Asahi Kasei Pharma Corporation (JP) 2009-12-09 — — EP disclosed
US-7618984-B2 Sulfonamide compound ASAHI KASEI PHARMA CORPORATION (JP) 2009-11-17 — — US disclosed
US-20090048223-A1 Sulfonamide compound ASAHI KASEI PHARMA CORPORATION (JP) 2009-02-19 — — US disclosed
EP-1932841-A1 SULFONAMIDE COMPOUND Asahi Kasei Pharma Corporation (JP) 2008-06-18 — — EP disclosed
CN-100354264-C 5-substituted isoquinoline derivatives and drugs containing them ASAHI KASEI PHARMA CORP (JP) 2007-12-12 — — CN disclosed
US-20070179127-A1 Sulfonamide compound ASAHI KASEI PHARMA CORPORATION (JP) 2007-08-02 — — US disclosed
US-7094789-B2 5-substituted isoquinoline derivatives ASAHI KASEI PHARMA CORPORATION (JP) 2006-08-22 — — US disclosed
CN-1668600-A 5-substituted isoquinoline derivatives ASAHI KASEI PHARMA CORP (JP) 2005-09-14 — — CN disclosed
EP-1541559-A1 5-SUBSTITUTED ISOQUINOLINE DERIVATIVE Asahi Kasei Pharma Corporation (JP) 2005-06-15 — — EP disclosed
US-20050020623-A1 5-Substituted isoquinoline derivatives ASAHI KASEI PHARMA CORPORATION (JP) 2005-01-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020623-A1 5-Substituted isoquinoline derivatives MYLK, MYLK2, MYL12A CYP3A4 4458/4885LMNA 178/4885CYP1A2 3158/4885
US-11248004-B2 Substituted isoquinolines as rock kinase inhibitors ROCK1, ROCK2, CIT CYP3A4 3330/4885LMNA 1820/4885CYP1A2 1966/4885
US-20070179127-A1 Sulfonamide compound MYLK, MYLK2, MYLK3 CYP3A4 2078/4885LMNA 1303/4885CYP1A2 1727/4885
US-11912719-B2 Substituted isoquinolines as rock kinase inhibitors ROCK1, ROCK2, CIT CYP3A4 3330/4885LMNA 1820/4885CYP1A2 1966/4885
US-20090048223-A1 Sulfonamide compound ALK, AKT1, ARAF CYP3A4 2359/4885LMNA 2215/4885CYP1A2 1718/4885
US-20220119406-A1 SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS ROCK1, ROCK2, CIT CYP3A4 3330/4885LMNA 1820/4885CYP1A2 1966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.